Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Ovarian cancer screening and early detection in the general population.

Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB.

Rev Obstet Gynecol. 2011;4(1):15-21.

2.

Progress and challenges in screening for early detection of ovarian cancer.

Jacobs IJ, Menon U.

Mol Cell Proteomics. 2004 Apr;3(4):355-66. Epub 2004 Feb 5. Review.

3.

The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Brown PO, Palmer C.

PLoS Med. 2009 Jul;6(7):e1000114. doi: 10.1371/journal.pmed.1000114. Epub 2009 Jul 28.

5.

Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.

van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ.

Cancer. 2007 May 1;109(9):1887-96.

6.

Ovarian cancer screening: a look at the evidence.

Fields MM, Chevlen E.

Clin J Oncol Nurs. 2006 Feb;10(1):77-81. Review.

PMID:
16482731
7.

In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Cohen JG, White M, Cruz A, Farias-Eisner R.

World J Biol Chem. 2014 Aug 26;5(3):286-300. doi: 10.4331/wjbc.v5.i3.286. Review.

8.

[Screening methods for malignant ovarian tumors in adult women].

Milenković V, Sparić R, Atanacković J.

Srp Arh Celok Lek. 2005 Jan-Feb;133(1-2):72-5. Review. Serbian.

9.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

10.

The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ.

Gynecol Oncol. 2000 Jun;77(3):350-6.

PMID:
10831341
11.

Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms.

Hall KL, Dewar MA, Perchalski J.

Prim Care. 1992 Sep;19(3):607-20. Review.

PMID:
1410066
12.

[Ovarian cancer screening: recommendations for clinical pratice].

Amram-Benamran ML, Cochet S, Petignat P, Sappino AP.

Rev Med Suisse. 2010 May 26;6(250):1062, 1064, 1066-8. French.

PMID:
20564865
13.

Prospective on ovarian cancer: why prevent?

Hoskins WJ.

J Cell Biochem Suppl. 1995;23:189-99. Review.

PMID:
8747396
14.
15.

The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.

Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE.

Am J Obstet Gynecol. 2005 Apr;192(4):1214-21; discussion 1221-2.

PMID:
15846205
16.

Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.

17.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
18.

Optimum screening interventions for gynecologic malignancies.

Lea JS, Miller DS.

Tex Med. 2001 Feb;97(2):49-55. Review.

PMID:
11233059
19.

Screening for ovarian cancer.

Lewis S, Menon U.

Expert Rev Anticancer Ther. 2003 Feb;3(1):55-62. Review.

PMID:
12597350
20.

Long-term follow-up of the Stockholm screening study on ovarian cancer.

Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V Jr, Sjövall K.

Gynecol Oncol. 2000 Dec;79(3):466-70.

PMID:
11104621
Items per page

Supplemental Content

Write to the Help Desk